Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.76
-0.05 (-0.30%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution.
Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma, Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 90 |
| CEO | Rick Winningham |
Contact Details
Address: 901 Gateway Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 808 6000 |
| Website | theravance.com |
Stock Details
| Ticker Symbol | TBPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583107 |
| CUSIP Number | G8807B106 |
| ISIN Number | KYG8807B1068 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rick E. Winningham M.B.A. | Chief Executive Officer and Director |
| Aziz Sawaf C.F.A. | Senior Vice President and Chief Financial Officer |
| Brett A. Grimaud Esq. | Senior Vice President, General Counsel and Secretary |
| Stuart Knight | Senior Vice President of IT&I and Chief Information Officer |
| Rhonda F. Farnum | Chief Business Officer and Senior Vice President of Commercial and Medical Affairs |
| Stacy L. Pryce | Senior Vice President and Chief Strategy Officer |
| Dr. Aine Miller Ph.D. | Senior Vice President of Development and Head of Ireland Office |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 25, 2026 | SCHEDULE 13D/A | Filing |
| Mar 23, 2026 | 10-K | Annual Report |
| Mar 19, 2026 | 8-K | Current Report |
| Mar 16, 2026 | 144 | Filing |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 8, 2025 | 8-K | Current Report |